IPI-145
- Duvelisib - INK-1197
- Optical Purity: 99% e.e.
- Soluble in DMSO
- MF: C22H17ClN6O
- MW: 416.86
Description
IPI-145 is an orally bioavailable PI3K/P110δ/γ isoform-specific inhibitor, with Ki values: P110δ (23 pM), P110γ (243 pM), p110α (25900 pM) and p110β (1564 pM). IPI-145 exerts profound effects on adaptive and innate immunity by inhibiting B and T cell proliferation, blocking neutrophil migration, and inhibiting basophil activation. IPI-145 showed potent activity in collagen-induced arthritis, ovalbumin-induced asthma, and systemic lupus erythematosus rodent models.
More Information
| Parent CAS No. | 1201438-56-3 |
|---|---|
| Chemical Name | (S)-3-(1-(9H-Purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one |
| extra_info | Sold in collaboration with Chemietek |
| SMILES | C1C(Cl)=C2C(=O)N(C3C=CC=CC=3)C([C@H](C)NC3N=CN=C4NC=NC=34)=CC2=CC=1 |&1:14,r| |
| MFCD | N.A. |
| InChi | N.A. |
| InChiKey | N.A. |
| CID | N.A. |
| Short Description | PI3K inhibitor |
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1281 | BEZ 235 |
From $55.00 |
| 1282 | BAG 956 |
From $104.50 |
| 1334 | PIK 75 hydrochloride |
From $77.00 |
| 1362 | PIK 90 |
From $93.50 |
| 1366 | LY 294002 |
From $77.00 |
| 1377 | GDC 0941 bismesylate |
From $88.00 |
| 1380 | PI 103 hydrochloride |
From $66.00 |
| 1417 | TGX 221 |
From $77.00 |
| 1424 | AS 252424 |
From $93.50 |
| 1436 | AS 252424 bispotassium salt |
From $104.50 |
| 1520 | NVP-BBD130 |
From $137.50 |
| 1596 | GSK 2126458 |
From $55.00 |
| 1706 | XL PI3K/mTOR inhibitor |
From $132.00 |
| 1719 | D 106669 |
From $93.50 |
| 1782 | GDC 0980 |
From $88.00 |
| 1797 | NVP-BKM120 |
From $99.00 |
| 1807 | PKI 587 |
From $99.00 |
| 1831 | A 66 |
From $104.50 |
| 1855 | PF 04691502 |
From $99.00 |
| 1912 | GSK 2636771 dihydrochloride |
From $115.50 |
| 2029 | NVP-BGT226 |
From $132.00 |
| 2039 | CZC 24832 |
From $104.50 |
| 2168 | IC 87114 |
From $93.50 |
| 2170 | CAL 101 |
From $104.50 |
